ESMO2016 Eye on ESMO: Day 2 - gamechangers take centre stage Novartis’ phase 3 advanced breast cancer therapy ribociclib shows promise
ESMO2016 Cancer market commentary: 3 highlights from ESMO (Part 1) Commentary on key cancer data from ESMO by Stephanie Hawthorne
News J&J jumps on the MFN pricing train Johnson & Johnson is the latest pharma group to agree a Most-Favoured Nation (MFN) drug pricing deal with the Trump administration to avert tariffs.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
